Neuronetics, Inc.
STIMNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $149.2M | $74.9M | $71.3M | $65.2M | $55.3M | $49.2M |
| Operating income | −$31.4M | −$34.6M | −$30.6M | −$35.1M | −$27.6M | −$10.4M |
| Net income | −$39.0M | −$43.7M | −$30.2M | −$37.2M | −$31.2M | −$12.6M |
| Total assets | $141.6M | $140.9M | $115.8M | $116.9M | $141.2M | $78.7M |
| Total liabilities | $115.3M | $109.1M | $81.6M | $59.8M | $56.0M | $53.2M |
| Equity | $22.4M | $27.7M | $34.2M | $57.1M | $85.2M | $25.5M |
| EPS (diluted) | $-0.59 | $-1.38 | $-1.05 | $-1.38 | $-1.22 | $-1.46 |
| Shares out. | 65.8M | 29.8M | 28.4M | 26.6M | 25.4M | 18.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −21.1%
- Net margin
- −26.1%
- Return on equity
- −174.3%
- Return on assets
- −27.6%
- Return on capital (ROCE)
- −28.3%
- Liabilities / assets
- 81.5%
- Debt / equity
- 5.15×
- Book value / share
- $0.34
- Revenue growth (YoY)
- 99.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.42distress
- Accruals / assets
- −13.2%clean
- Beneish M-Score
- -2.59normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Chernett JoreyActivist (13D)May 27, 2026
- Parian Ultreia LpPassive (13G)Mar 17, 2026
- Madryn Asset Management, LpActivist (13D)Mar 4, 2026
- Kent Lake Pr LlcPassive (13G)Feb 14, 2025
- Parian Global Management LpPassive (13G)Nov 14, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rosengarten MeganDirector | May 28, 2026 | Grant | 30,000 | $0.00 |
| Muir Glenn PDirector | May 28, 2026 | Grant | 30,000 | $0.00 |
| Cucuz SashaDirector | May 28, 2026 | Grant | 30,000 | $0.00 |
| Conley Sheryl LDirector | May 28, 2026 | Grant | 30,000 | $0.00 |
| Cascella RobertDirector | May 28, 2026 | Grant | 36,250 | $0.00 |
| Amin AvinashDirector | May 28, 2026 | Grant | 30,000 | $0.00 |
| Chernett Jorey10% owner | May 19, 2026 | Buy | 100,000 | $1.17 |
| Chernett Jorey10% owner | May 12, 2026 | Buy | 475,000 | $1.34 |
| Chernett Jorey10% owner | Apr 20, 2026 | Buy | 100,000 | $1.58 |
| Madryn Asset Management, Lp10% owner | Jul 10, 2025 | Gift | 337,312 | $0.00 |
| Chernett Jorey10% owner | Mar 30, 2026 | Buy | 385,442 | $1.25 |
| Chernett Jorey10% owner | Mar 27, 2026 | Buy | 500,000 | $1.35 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.6M | 2.9 | -8.0% |
| Apr 30, 2026 | 10.5M | 6.2 | -4.1% |
| Apr 15, 2026 | 10.9M | 4.5 | +16.4% |
| Mar 31, 2026 | 9.4M | 3.4 | +0.2% |
| Mar 13, 2026 | 9.4M | 12.2 | -8.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 29, 2026
- Director / officer changeMay 22, 2026
- Results of operations · Regulation FD disclosureMay 5, 2026
- Entered a material agreement · Costs from exit or disposal · Director / officer change · Regulation FD disclosureApr 6, 2026
- Results of operations · Director / officer change · Regulation FD disclosureMar 17, 2026
- Entered a material agreementMar 2, 2026
- Director / officer changeFeb 25, 2026
- Results of operationsFeb 10, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SDMay 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 4May 29, 2026
- 8-KMay 29, 2026
- SCHEDULE 13D/AMay 27, 2026
- 8-KMay 22, 2026
- 4/AMay 21, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 3May 13, 2026
- 4OWNERSHIP DOCUMENTMay 13, 2026
- 10-QMay 5, 2026